ARCHIVES

Rev/Vel/Dex Response Rate High In Phase I/II Study

This article is from The Cancer Letter archive.

Vol. 31 No. 1 | January 25, 2008

Download PDF Visit The Full Archive

Related Articles

Zerhouni Appoints Kington As Deputy Director

February 14, 2003

A Patchwork Of Policies Emerges As Insurers Tighten Payments For ESAs.

March 30, 2007

Long-Term Estrogen Use May Increase Ovarian Cancer Risk

April 27, 2001

FDA Approves Afinitor Tablets For Advanced Breast Cancer

August 31, 2012

Funding Opportunities: NCI Grant Supplements For Mammalian Models

October 22, 1999

Final Results from CLEOPATRA Phase III Trial Show Perjeta Increased OS 15.7 Months

September 26, 2014